News

February 28, 2022

Lycia Therapeutics Strengthens Leadership Team with Appointment of Steve Staben, Ph.D. as Chief Scientific Officer

Download PDF Read More

September 9, 2021

Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures

Read More

August 25, 2021

Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders

Download PDF Read More

June 9, 2020

Versant Ventures Launches Lycia Therapeutics with $50 Million

Download PDF Read More